Haemonetics (HAE) Tops Q3 EPS by 10c; raises guidance

Haemonetics (NYSE: HAE) reported Q3 EPS of $1.04, $0.10 better than the analyst estimate of $0.94. Revenue for the quarter came in at $336 million versus the consensus estimate of $320.77 million.

GUIDANCE:

Haemonetics sees FY2024 EPS of $3.90-$4.00, versus the consensus of $3.89.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c